Latest Clinical Pipeline News

Aroa Biosurgery has reported its first quarter of positive operating cash flow since listing on the ASX in 2020, alongside robust revenue growth projections and new regulatory approvals across key international markets.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.